GANX (Gain Therapeutics) Short Interest


GANX Gain Therapeutics Inc GANX
31 GF Score
Price $1.72
! 2 Warning Signs
View Full Analysis

What is Gain Therapeutics Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

GANX vs EXOZ, HYFT, MAIA: Short Interest Comparison

For the Biotechnology subindustry, Gain Therapeutics's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gain Therapeutics Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gain Therapeutics's Short Interest distribution charts can be found below:

* The bar in red indicates where Gain Therapeutics's Short Interest falls into.


GANX
31GF Score
Gain Therapeutics Inc GANX
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gain Therapeutics Business Description

Address 4800 Montgomery Lane, Suite 220, Bethesda, MD, USA, 20814
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.
31GF Score

Get the complete analysis for GANX

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.72
Price